These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38327109)

  • 1. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention.
    Trepl J; Pasin C; Schneidawind D; Mueller NJ; Manz MG; Bankova AK; Abela IA
    Br J Haematol; 2024 May; 204(5):1908-1912. PubMed ID: 38327109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.
    Simone S; Pronzo V; Pesce F; Bavaro DF; Infante B; Mercuri S; Schirinzi A; Panaro A; Conte E; Belati A; Troise D; Pontrelli P; Conserva F; Gallo P; Panico M; Spilotros M; Lucarelli G; Saracino A; Stallone G; Di Serio F; Ditonno P; Gesualdo L
    J Nephrol; 2024 Jul; 37(6):1539-1550. PubMed ID: 38780697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tixagevimab-cilgavimab as pre-exposure prophylactic treatment against SARS-CoV-2 in kidney transplantation patients].
    Bravo González-Blas L; Menéndez García N; Fernández Prada M; Gago Fraile M; Suárez Fernández ML; Ridao Cano N
    Nefrologia (Engl Ed); 2024; 44(3):396-401. PubMed ID: 38331599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
    Jondreville L; D'Aveni M; Labussière-Wallet H; Le Bourgeois A; Villate A; Berceanu A; Bezsera SM; Thiebaut A; Boissard-Simonet M; Legrand M; Cornillon J; Rubio MT; Chevallier P; Nguyen S
    J Hematol Oncol; 2022 Nov; 15(1):169. PubMed ID: 36443846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
    Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
    Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
    Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
    Transpl Int; 2024; 37():12061. PubMed ID: 38328617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
    Falcone M; Tiseo G; Marchetti G; Kalo J; Galfo V; Occhineri S; Almerigogna F; Matucci T; Riccardi N; Suardi LR; Rina I; Sijoni L; Caparello MC; Cassano Cassano R; Del Giudice ML; Franciosa M; Facella F; Tancredi G; Fazzi R; Galimberti S
    Leuk Lymphoma; 2024 Oct; 65(10):1474-1481. PubMed ID: 38832710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
    Vergori A; Cozzi Lepri A; Chiuchiarelli M; Mazzotta V; Metafuni E; Matusali G; Siciliano V; Paulicelli J; Alma E; Siniscalchi A; Sica S; Abruzzese E; Fantoni M; Antinori A; Cingolani A
    Int J Infect Dis; 2024 Jul; 144():107042. PubMed ID: 38614231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
    Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
    Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
    Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.
    Basoulis D; Mastrogianni E; Karamanakos G; Gkoufa A; Georgakopoulou VE; Makrodimitri S; Gamaletsou MN; Markogiannakis A; Sipsas NV
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
    Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N
    Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Yan VKC; Yang Y; Wan EYF; Lai FTT; Chui CSL; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Drug Saf; 2024 Oct; 47(10):1025-1037. PubMed ID: 38916712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
    Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
    Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab.
    Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Dec; 30(12):1222-1227. PubMed ID: 38777151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
    Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
    Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.